Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Persons with Intellectual Disability

Dr Nicole Eady MB BS (UCL 2007) iBSc, MSc, MRCPsych

Central and North West London NHS Foundation Trust, Harrow Community Learning Disability Team, First Floor, 839 Honeypot Lane, Stanmore, Middlesex HA7 1AT.

Tel: 020 8952 5763 Fax: 020 8952 6547 email: nicole.eady@nhs.net

Dr Ken Courtenay MB BCh FRCPsych MRCGP

Consultant Psychiatrist, Haringey Learning Disabilities Partnership 40 Cumberland Road London N22 7SGUK. Tel: +44 20 8489 1395; E-mail: k.courtenay@ucl.ac.uk

Dr André Strydom MBChB MRCPsych MSc PhD

Reader in Intellectual Disabilities, UCL Division of Psychiatry, Charles Bell House, 2nd Floor, 67-73 Riding House Street, London W1W 7EJ, and The LonDownS Consortium

Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Persons with Intellectual Disability

Abstract:

Given medical and social advances, the life expectancy of individuals with intellectual disability (ID) has increased dramatically, leading to a generation of older individuals with such disabilities. This review focuses on the pharmacological treatment of behavioral and psychiatric symptoms and disorders in older persons with ID. Older adults with ID often present with medical co-morbidities and mental health issues. Medication management of behavioral and psychiatric problems is complicated by a higher risk for adverse events, lack of decision-making capacity, and complex care networks. Some studies have shown that persons with ID and co-morbid mental disorders are undertreated in comparison to individuals with similar disorders in the general population, resulting in poorer outcomes. However, older adults with ID are also at risk of polypharmacy and older age is a risk factor for development of side-effects. A general principle is that medication treatment for psychiatric disorders in older persons with ID should be started at low dosages and be increased cautiously while monitoring response and side-effects. The use of psychotropic drugs for older persons with ID and behavioral problems remains controversial, particularly in those with dementia.

Key points:

- The growing population of older persons with ID has an increased risk for aging related health issues such as dementia, on a background of lifelong disabilities and physical health and psychiatric co-morbidities.

Management of psychiatric symptoms in older persons with ID

- Medication management of behavioral and psychiatric problems may be complicated by a higher risk for adverse events, lack of decision-making capacity, and complex care networks.
- Medication management of specific conditions is however beneficial, but in general, medication should be started at low doses, with careful titration against response, and regular monitoring for side-effects.

1. Introduction

Intellectual Disability (ID) is defined by the World Health Organization (WHO) as significant cognitive impairment associated with impairment of skills manifested during the developmental period. Cognitive impairment in people with ID is categorized as two standard deviations below the norm for intellectual quotient (IQ) with a level below 70 in the ID range. The development of social and adaptive skills is central in the definition of ID where the person requires support to maintain their level of functioning. Such deficits must have their origins in childhood, which contrasts with cognitive impairment acquired in adulthood. Classification systems categorize levels of IQ in to mild, moderate, severe, and profound. In general, people with mild ID require less support in daily living skills than others but they are often more vulnerable to exploitation by others and engage in more high risk lifestyle activities for example, cigarette smoking. People with intellectual impairment comprise between 2.5% to 3% of the general population based on statistical estimates in the population where ID is two standard deviations below the norm for IQ, but the global prevalence estimate of ID (i.e. intellectual and functional impairment) is 1.03% (1).
ID is associated with greater degrees of health inequalities than in the general population and people have more co-morbid conditions affecting all body systems especially the nervous system (2). The prevalence of epilepsy for example, is greater in people with ID than in the general population (3). The prevalence of mental disorders and behavioral problems associated with associated disorders such as autism is greater in people with ID (4). Therefore, people with ID are, from childhood, more likely to require drug therapy to manage such long-term conditions and as such are exposed to the risks of using medication throughout their lives.

The life expectancy of people with ID has risen over the past 50 years (5) which could be due to advances in medical technology and improved social care benefitting people with moderate to severe ID. Changes in societal attitudes towards people with ID and awareness

of health inequalities have also had beneficial effects. The life expectancy of people with Down syndrome (DS) has risen from 12 years in the 1940s to 60 years currently largely because of cardiac surgery interventions (6). In spite of this, people with ID continue to die younger than their peers in the general population which is in part due to health and social factors that may be amenable to change (7). Nevertheless, there are increasing numbers of older adults with ID who may require considerable care inputs. The average annual cost of care for older individuals with ID in the UK is approaching £50,000 ($71,952; €54,034 at 2013 rates for purchasing power parity), most of which is accounted for by personal care rather than health care costs, with mental health problems being an important predictor of costs)(8). Appropriate treatment and management of behavioral and psychiatric symptoms may therefore help to reduce the burden on caregivers as well as the cost of care.

In this review, we will focus on the behavioral and psychiatric symptoms associated with aging in ID and the implications for medication management of these conditions in this population.

2. Physical health issues

A review of medication management in the ID population would not be complete without acknowledging the complex health needs of this population, which affect the selection of treatments for behavioral and psychiatric symptoms, and their effectiveness and tolerability. People with ID are more vulnerable to developing acute and chronic health problems for a variety of reasons related to either dependency as a consequence of ID, or to lifestyle factors for example, diet. An example of an acute health condition is the development of bronchopneumonia in a person with severe ID who has difficulties swallowing because of impaired reflexes. Older people with ID are more disposed to long-term conditions such as diabetes mellitus(9). Their management often requires drug interventions in the long-term

and thus exposing them to the side effects of medication over a long period of time as they age.

People with ID often use combinations of medication that potentially interact with each other and have implications for other drugs added to current drug regimens. Clinicians need to be aware of the regimens that people use when prescribing new medication because of the pharmacokinetics of drugs that could affect the metabolism of other agents through enzyme-induction or competitive binding to proteins thus affecting serum levels of drugs. Equally, clinicians need to consider the impact of weight-inducing medication on the long-term health of the person and their subsequent quality of life.

People with ID experience the same range of physical and mental health difficulties as in the general population but their level of functioning and cognitive impairments may predispose them to developing health problems. The rates of cardiovascular diseases in older adults with ID are similar to those in the general population (9)(10) while neurological disorders, especially epilepsy occur at higher rates in people with ID (3). Overweight and obesity is also an increasing problem (9). In a recent large scale survey of older adults (age 55+) with ID in Europe, rates of smoking and use of alcohol were lower than in the general population but were higher with older age. More than 60% of older adults with ID had a sedentary lifestyle. Cataract, hearing disorder, diabetes, hypertension, osteoarthritis/arthrosis, and osteoporosis were positively associated with advancing age in those with ID, but rates of epilepsy declined with age (11). The aetiological factors for these health problems are multi-factorial based in the etiology of the ID for example neurological development, or in environmental and social factors such as poor housing or impoverished diet and sedentary lifestyle.

3. General issues regarding medication management in persons with ID

Prescription of medication for the treatment and management of behavioral and psychiatric symptoms in persons with ID requires careful consideration. A full discussion of all the

issues is beyond the scope of this review, and has been reviewed elsewhere (12,13). The general principles of medication treatment of psychiatric disorders in persons with ID include:

- Decision making capacity should be assessed, and if the person does not have capacity to decide about their own treatment, appropriate legal and ethical frameworks should be followed to enable treatment depending on the jurisdiction
- Safe management and dispensing of medication should be carefully considered, and the use of blister packs, dosette boxes and medication alarm systems may be useful, as well as identifying a responsible person to assist with appropriate management of medication
- Persons with ID often have complex care networks and it is important to inform all involved persons of any changes of treatment
- Side effects and response to treatment should be monitored, using standardized instruments if possible, with due consideration to the communication needs of the individual. The carers of those with limited communication abilities should be provided with clear instructions on how to monitor for side effects.

4. Mental health disorders in older adults with ID

Mental health disorders have a greater prevalence among people with ID with higher rates of psychosis, dementia, and mood disorders than the general population (4)(14)(15). Drug management of such disorders in people with ID is important because of the benefits to the person in treating the disorders but the choice and management of medication should be undertaken by a clinician knowledgeable in the mental healthcare of people with ID. However, there is very little evidence to guide prescribing of behavioral and psychiatric symptoms in this population because people with ID have been historically

underrepresented in randomized controlled medication trials (16). We will summarize generally accepted recommendations, and highlight specific findings if available.

4.1. Treatment of mood disorders in older adults with ID

Depression is common in adults with ID (4) and is more likely to follow a chronic course (17). In older adults with ID, increased depressive symptoms were significantly and positively correlated with age, and were also associated with chronic diseases such as heart failure, stroke, chronic obstructive pulmonary disease, coronary artery disease, diabetes mellitus and malignity in the previous 5years (18). In a large survey of depression in older adults with ID (aged 50 and older) in the Netherlands, major depressive disorder was prevalent in 7.6% (95% CI: 5.2–11.0), anxiety disorders in 4.4% (95% CI: 2.6–7.0) and both disorders in 0.7% (95% CI: 0.2–1.6). There was no relationship with gender, age or level of ID (19).

In Taiwan, patients with ID and Bipolar affective disorder were younger than patients with Bipolar Affective Disorder without ID, but had longer periods of hospitalization and were more likely to remain as in-patients, possibly due to receiving significantly lower dosages of medication such as antipsychotics, mood stabilisers and lithium (20). These findings are unlikely to be unique to Taiwan and suggest that mood disorders remain under-recognised and under-treated in persons with ID, which affect longer term outcomes. However, use of antidepressants particularly selective serotonin reuptake inhibitors (SSRIs) have been increasing in the ID populations since the mid-1990s in the US (21). The increased use of SSRIs with fewer side effects was interpreted as evidence for improving skill in diagnosing and treating depressive disorders in this population.

We were not able to identify specific studies or guidelines for medication treatment of depression in older individuals with ID. In general, the treatment guidelines for depression in the general population are appropriate to use, including the UK's NICE guideline (22) and

the American Psychiatric association's practice guideline (23).

4.2. Use of antipsychotic drugs in older adults with ID

A large survey of antipsychotic prescribing to 2319 adults with ID (all ages) in the UK found that the commonest indications were for psychotic illness (42%) and anxiety (42%), while behavioral problems such as aggression (38%), threatening behavior (30%) and self-harm (13%) were also common indications (24). Risperidone was the most prescribed antipsychotic, particularly for agitation and anxiety, at a median dose of 2mg per day, followed by olanzapine which was most often prescribed for psychotic symptoms. The second most common drug for psychosis was quetiapine. Use of older antipsychotics was common, particularly chlorpromazine which was used for overt aggression, and haloperidol for agitation and anxiety. This survey was undertaken before use of aripiprazole became more common in the UK, and it is likely that this drug may increasingly be used for psychosis or behavioral disturbances associated with ID or autism following some evidence of efficacy (25)(26). Guidelines have been produced for the use of newer antipsychotic drugs in persons with ID (27), which included practical drug review checklists, as well as for clozapine (28). These drugs need to be used cautiously in older adults with ID, particularly in those with co-morbidities:

- dementia and cerebrovascular disease, which are relative contraindications for newer antipsychotics due to an increased risk for stroke
- olanzapine and quetiapine have potential antimuscarinic activity, which in combination with other medications with antimuscarinic activity may significantly impact on cognition in older individuals with ID, as well as cause problems with gastrointestinal motility, urinary retention, and narrow-angle glaucoma (27).

- clozapine, quetiapine, olanzapine and risperidone may cause hypotension and clinicians should use these drugs cautiously in older adults with ID prescribed with antihypertensives.

- Metabolic syndrome is a well-known complication of newer antipsychotics (particularly olanzapine and clozapine), and risk factors such as obesity and diabetes are common in older adults with ID, particularly those with mild intellectual impairment. Concomitant use of medications known to elevate blood glucose or cause weight gain should be avoided as far as is possible in older adults with ID. It is also recommended to document weight, BMI, glucose levels, glycosylated hemoglobin levels, electrolytes and liver function tests before starting these drugs (27) though often it is not done in practice (29). The use of newer (atypical) antipsychotics was associated with higher diastolic blood pressure and elevated fasting glucose in adults prescribed antipsychotic drugs for more than 1 year (30).

4.3. Medication management of problem behavior in older adults with ID

There is some evidence for the use of medication for problem behavior in adults with ID particularly those with co-morbid autism (13). The best evidence is for risperidone, with multiple trials showing its efficacy (26). The management of problem behavior in people with ID can include the use of other medications to help manage behavior that could be attributed to mental disorder for example, anxiety, mood disorder, or psychosis. The etiological cause of the problem behavior can be difficult to elucidate and medication is often used to manage it without clear indications for example, anti-psychotic drugs can be used for their sedative or anxiolytic properties rather than to treat psychotic signs. In doing this, the person may be exposed to the adverse effects of medication particularly if used over a prolonged period of time with the potential of interacting with other drugs, particularly in older persons. Furthermore, a controlled discontinuation study of long-term antipsychotics for behavioral

disturbance in persons with ID (aged 15 - 66; n = 98), in which 43 achieved complete discontinuation, showed that a significant proportion of individuals benefited from reduction or withdrawal of the medication with improvement in clinical symptoms (30). Most guidelines concerning medication use for problem behavior therefore recommend careful titration against response, regular monitoring for side-effects and using short treatment periods if possible (12). In general, one medication should be used at a time, within standard recommended dosage range and the opportunities for monotherapy should be exhausted before a combination therapy is considered. Appropriate follow-up visits must be arranged, and the potential for dosage reduction or discontinuation of medication should be regularly considered during the course of treatment (16).

5. Dementia in older adults with ID

As the average life expectancy in the ID population increases, so does the number of individuals experiencing complications of older age, such as dementia. Dementia is defined as a chronic, progressive mental disorder which adversely affects higher cortical functions including memory, language and orientation (31) and associated with increasing morbidity and mortality and imposes significant costs (32). It is therefore important that evidence-based treatments for dementia in ID are developed and evaluated.

Dementia in ID often has an atypical presentation. Changes in behavior or personality may precede the traditional cognitive symptoms, particularly in those with more severe ID and DS, and the onset of seizures is also common (8).

A number of anti-dementia medications including acetlycholinesterase inhibitors (AIs) such as donepezil, rivastigmine and galantamine and the N-methyl-D-aspartate (NMDA) antagonists memantine have been developed and there is a strong evidence-base to support their prescription in the non-ID population (33). These medications are noted to have a beneficial effect on the behavioral and psychiatric symptoms of dementia in addition to maintaining cognitive functions in the short to medium term (34). The prescription of anti-

dementia medication is supported by national and international guidance including that in the UK (35), USA (36) and Europe (37).

AIs and NMDA antagonists are not believed to have disease modifying properties and are therefore not used to prevent the long-term histopathological progression of disease. However in the short to medium term they have been shown to slow the clinical deterioration.

5.1. Management of dementia in Down syndrome

Down syndrome (DS) is neuropathologically associated with the risk of developing an Alzheimer-like dementia (38). Donepezil, from the anticholinesterase class of medications, is the most commonly prescribed anti-dementia medication in this population. A review of the literature found a few small controlled studies (39)(40)(41) which confirm that donepezil is well tolerated in the DS population. These studies have some methodological flaws including the small sample size, choice of controls, and length of follow-up. Other than commenting on safety and the side effect profile, it is not possible to draw conclusions on the efficacy of donepezil on cognition or functioning, or the control of associated behavioral and psychiatric symptoms in the DS dementia population. Further evidence is required, including from non-randomized designs as it may not be possible to complete further randomised control studies.

There are no published studies on the efficacy of galantamine in the DS population.

A recent small non-randomized observational study showed a significant difference in cognitive functioning ($p=0.048$) and behavior ($p=0.05$) between a non-treatment group with DS and those prescribed rivastigmine either as oral or transdermal formulation (42). The authors noted that transdermal rivastigmine had improved compliance and was well tolerated in the DS population. Another small placebo controlled trial of rivastigmine in older adults with DS showed a reduction in the rate of deterioration on markers of cognition and behavior between the treatment and control groups after 24 weeks (43). The differences

between the control and treatment group were not statistically significant. Both of the above studies have the limitations of being small and having short follow-up periods.

The current literature on memantine does not support its use in clinical practice in DS. A recent prospective double-blind, randomised control trial compared memantine with a placebo in patients with DS (44). All participants in the study were over 40 years of age of which a third had a diagnosis of dementia. There was no statistical significance between the groups at one year on measures of functioning, behavior or cognition. The authors concluded that memantine is not effective in the treatment of dementia in the DS population.

5.2. Management of dementia in the Non-DS ID population

People with DS are the population among people with ID who are most at risk of developing dementia. Dementia may also be more common in older adults with ID who do not have DS, with prevalence rates of up to 18% in those aged 65 and older (14). Incidence rates peak at age 70-75 (45).

However, among people with ID but who do not have DS (non-DS ID) there is no published research on the pharmacological treatment of dementia despite a recent estimate of the incidence of dementia among them being up to 4 times higher than the general population (45). Current clinical practice varies widely with clinicians often referring to the evidence base for the DS population and the non-ID population. Clinicians, carers, and patients often lack awareness of the early signs of dementia which can result in a delay in offering dementia-specific treatments (46).

5.3. Management of behavioral and psychiatric symptoms associated with dementia in ID

Dementia in ID is frequently associated with co-morbidities including psychiatric presentations, for example depression, and behavioral problems (8). Some of these psychiatric co-morbidities including problem behavior may be noted to improve with the

prescription of dementia medication listed above. Antipsychotic drugs have been widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease in the general population, but following a large randomized trial it was concluded that adverse effects offset advantages (47). In some countries such as the UK, recent guidelines consequently suggested that antipsychotics are overused in older adults with dementia in the general population and that the potential benefit of their use is likely to be outweighed by the adverse effects in many cases. Whilst not prohibiting use of such drugs, a key recommendation was to avoid the prescription of newer antipsychotics in adults with dementia (48). Pharmacological treatment of any co-morbidity would therefore need to be in accordance with the guidance on managing co-morbidity in general guidance by the relevant national body such as the American Psychiatric Association (USA) or the Royal College of Psychiatrists (UK).

Medical co-morbidities are a common cause of mortality in the older adult ID population and require prompt review in any person presenting with a change in behavior. The prescriber should also be aware of the associated risk of polypharmacy and drug interactions in this population. Although outside the scope of this review, changes in support plans and access to psychological interventions both have an important role in the treatment of the behavioral and psychiatric symptoms of dementia (49).

Sleep difficulties are noted to increase in older age groups, especially in those with dementia (50). Behavioral difficulties secondary to the day-night routine is common. Melatonin is noted to be effective in reducing sleep onset latency in the ID population (51) although there are no published trials reviewing the safety or efficacy of melatonin prescription in the ID dementia population.

6. Polypharmacy and prescribing patterns

In a large study of psychotropic prescribing patterns in the USA comparing persons with ID with a dual diagnosis of co-morbid psychiatric disorders against those with normal ability with psychiatric diagnoses, it was found that antidepressants and antipsychotics were prescribed at lower rates for those with an ID, suggesting that psychiatric conditions in the ID population were often undertreated. However, polypharmacy rates were higher for adults with ID (52) and rates of prescribing of antipsychotics and antidepressants have been increasing over the past few decades (21).

Prescribing patterns are changing with prescribers moving away from medication management of behavioral issues as found in a recent study of psychotropic drug prescribing in adults with ID of all ages (mean age 49 years) in New York State (21). Although 58% of these adults with ID were prescribed one or more psychotropic drug, in most cases the indication was a diagnosed co-morbid mental disorder and only 13% were prescribed psychotropic drugs solely for control of behavioral problems (21). Age had no effect on the likelihood to be prescribed antipsychotics.

One group from the Netherlands described the side effect profiles associated with longer term (more than 1 year) antipsychotic use for behavioral problems in persons with ID with a mean age of 49.8 years (30). Extrapyramidal symptoms were present in 53%, overweight and obesity in 46%, and the metabolic syndrome in 11%. Hyperprolactinaemia was present in 17%. Older age and more severe ID were associated with increased rates of side-effects, particularly dyskinesia.

7. Conclusions and further research

Older adults with ID often present with medical co-morbidities and mental health issues. Many older individuals may have been prescribed long-term medication for psychiatric disorders such as autism but they may be more sensitive to the development of side effects particularly of anti-psychotics. Some studies have shown that persons with ID and co-morbid mental disorders are undertreated in comparison to individuals with similar disorders

in the general population resulting in poorer outcomes. However, older adults with ID are also at risk of polypharmacy and older age may be a risk factor for development of some side-effects. A general principle is that medication treatment for psychiatric disorders in older persons with ID should be started at low dosages and be increased cautiously while monitoring response and side-effects. The use of psychotropic drugs for persons with ID and behavioral problems remain controversial, particularly in older adults with dementia, and current guidelines are to use alternative treatments such as behavioral interventions as first-line option. If psychotropic drugs are used they should be carefully monitored and used for short periods. It remains to be seen whether the latest generation of antipsychotics such as aripiprazole are safer or better tolerated in older persons with ID.

Dementia is a common problem in this population and medication treatments for dementia in those with ID are broadly safe and well-tolerated. Sleep problems may respond to treatment with melatonin. There remains however a lack of strong evidence to support the clinical effectiveness of most medication treatments in this population given the current lack of well-designed, adequately powered studies.

Acknowledgements:

This work was partially funded by a Wellcome Trust Strategic Award (grant number: 098330/Z/12/Z) conferred upon The London Down Syndrome (LonDownS) Consortium). Dr Strydom was an investigator on medication trials in Down syndrome and Fragile X syndrome sponsored by Roche. Dr Courtenay and Dr Eady do not have conflicts of interests to declare.

Bibliography

1. Maulik P, Mascherenhas MN, Mathers CD, Dua T, Saxena S. Prevalance of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32:419–36.

2. Emerson E, Baines S, Allerton L, Welch V. Health Inequalities & People with Learning Disabilities in the UK [Internet]. 2011. Available from: http://www.improvinghealthandlives.org.uk/securefiles/141107_0947//IHaL%202011-09%20HealthInequality2011.pdf

3. Matthews T, Weston N, Baxter H, Felce D, Kerr M. A general practice-based prevalence study of epilepsy among adults with intellectual disabilities and of its association with psychiatric disorder, behaviour disturbance and carer stress. J Intellect Disabil Res. 2008 Feb 1;52(2):163–73.

4. Cooper S-A, Smiley E, Morrison J, Williamson A, Allan L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry. 2007 Jan 1;190(1):27–35.

5. Bittles AH, Petterson BA, Sullivan SG, Hussain R, Glasson EJ, Montgomery PD. The Influence of Intellectual Disability on Life Expectancy. J Gerontol A Biol Sci Med Sci. 2002 Jul 1;57(7):M470–2.

6. Glasson E, Sullivan S, Hussain R, Petterson B, Montgomery P, Bittles A. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet. 2002 Nov 1;62(5):390–3.

7. Glover G, Ayub M. How people with learning disabilities die. [Internet]. 2010. Available from: http://www.improvinghealthandlives.org.uk/publications/year/2010

8. Strydom A, Shooshtari S, Lee L, Raykar V, Torr J, Tsiouris J, et al. Dementia in Older Adults With Intellectual Disabilities—Epidemiology, Presentation, and Diagnosis. J Policy Pract Intellect Disabil. 2010 Jun 1;7(2):96–110.

9. Haveman M, Heller T, Lee L, Maaskant M, Shooshtari S, Strydom A. Major Health Risks in Aging Persons With Intellectual Disabilities: An Overview of Recent Studies. J Policy Pract Intellect Disabil. 2010 Mar 1;7(1):59–69.

10. Jansen J, Rozeboom W, Penning C, Evenhuis HM. Prevalence and incidence of myocardial infarction and cerebrovascular accident in ageing persons with intellectual disability. J Intellect Disabil Res. 2013;57(7):681–5.

11. Haveman M, Perry J, Salvador-Carulla L, Walsh PN, Kerr M, Van Schrojenstein Lantman-de Valk H, et al. Ageing and health status in adults with intellectual disabilities: Results of the European POMONA II study. J Intellect Dev Disabil. 2011 Mar 1;36(1):49–60.

12. Deb S, Kwok H, Bertelli M, Salvador-Carulla L, Bradley E, Torr J, et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry. 8(3):181–6.

13. Sawyer A, Lake JK, Lunsky Y, Liu S-K, Desarkar P. Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: A systematic review. Res Autism Spectr Disord. 2014 Jul;8(7):803–13.

14. Strydom A, Livingston G, King M, Hassiotis A. Prevalence of dementia in intellectual disability using different diagnostic criteria. Br J Psychiatry. 2007 Aug 1;191(2):150–7.

15. Strydom A, Hassiotis A, Livingston G. Mental Health and Social Care Needs of Older People with Intellectual Disabilities. J Appl Res Intellect Disabil. 2005 Sep;18(3):229–35.

16. Häßler F, Thome J, Reis O. Polypharmacy in the treatment of subjects with intellectual disability. J Neural Transm. 2014 May 25;1–8.

17. RICHARDS M, MAUGHAN B, HARDY R, HALL I, STRYDOM A, WADSWORTH M. Long-term affective disorder in people with mild learning disability. Br J Psychiatry. 2001 Dec 1;179(6):523–7.

18. Hermans H, Evenhuis HM. Factors associated with depression and anxiety in older adults with intellectual disabilities: Results of the healthy ageing and intellectual disabilities study. Int J Geriatr Psychiatry. 2013;28(7):691–9.

19. Hermans H, Beekman ATF, Evenhuis HM. Prevalence of depression and anxiety in older users of formal Dutch intellectual disability services. J Affect Disord. 2013 Jan 10;144(1–2):94–100.

20. Wu C-S, Desarkar P, Palucka A, Lunsky Y, Liu S-K. Acute inpatient treatment, hospitalization course and direct costs in bipolar patients with intellectual disability. Res Dev Disabil. 2013 Nov;34(11):4062–72.

21. Tsiouris JA, Kim S-Y, Brown WT, Pettinger J, Cohen IL. Prevalence of Psychotropic Drug Use in Adults with Intellectual Disability: Positive and Negative Findings from a Large Scale Study. J Autism Dev Disord. 2013 Mar 1;43(3):719–31.

22. NICE. Dementia [Internet]. NICE. [cited 2012 Nov 15]. Available from: http://www.nice.org.uk/

23. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2010;

24. Paton C, Flynn A, Shingleton-Smith A, McIntyre S, Bhaumik S, Rasmussen J, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of learning disability services: findings of a national audit. J Intellect Disabil Res. 2011;55:655–74.

25. Deb S, Farmah BK, Arshad E, Deb T, Roy M, Unwin GL. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder – A systematic review. Res Dev Disabil. 2014;35(3):711–25.

26. Cohen D, Raffin M, Canitano R, Bodeau N, Bonnot O, Perisse D, et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord. 2013;7(1):167–75.

27. De Leon J, Greenlee B, Barber J, Sabaawi M, Singh N. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil. 30(4):613–69.

28. Sabaawi M, Singh N, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil. 2006;27(3):309–36.

29. Teeluckdharry S, Sharma S, O'Rourke E, Tharian P, Gondalekar A, Nainar F, et al. Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability. J Intellect Disabil. 2013 Sep 1;17(3):223–35.

30. De Kuijper G, Mulder H, Evenhuis H, Scholte F, Visser F, Hoekstra PJ. Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics. Res Dev Disabil. 2013 Sep;34(9):2799–809.

31. Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer's disease. National Insitute for Health and Clinical Excellence; 2011.

32. Sheehan R, Ali A, Hassiotis A. Dementia in intellectual disability: Curr Opin Psychiatry. 2014 Mar;27(2):143–8.

33. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 May;10(3):195–203.

34. Cummings J, McRae T, Zhang R. Effects of Donepezil on Neuropsychiatric Symptoms in Patients With Dementia and Severe Behavioural Disorders. Am J Geriatr Psychiatry. 2006;

35. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. 2012 [cited 2014 Nov 7]; Available from: http://www.ncbi.nlm.nih.gov/books/NBK97263/

36. Segal-Gidan F, Cherry D, Jones R, Williams B, Hewett L, Chodosh J. Alzheimer's Disease Management Guideline: Update 2008. Alzheimers Dement. 2011 May;7(3):e51–9.

37. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010 Oct 1;17(10):1236–48.

38. Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, et al. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology. 2010;75:1639–44.

39. Lott IT, Osann K, Doran E, Nelson L. Down syndrome and alzheimer disease: Response to donepezil. Arch Neurol. 2002 Jul 1;59(7):1133–6.

40. Prasher VP, Huxley A, Haque MS. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study. Int J Geriatr Psychiatry. 2002 Mar 1;17(3):270–8.

41. Prasher VP, Adams C, Holder R. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study. Int J Geriatr Psychiatry. 2003 Jun 1;18(6):549–51.

42. Prasher VP, Sachdeva N, Adams C, Haque MS. Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study. Int J Geriatr Psychiatry. 2013 Feb 1;28(2):219–20.

43. Prasher VP, Fung N, Adams C. Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry. 2005 May 1;20(5):496–7.

44. Hanney M, Prasher V, Williams N, Jones E, Aarsland D, Corbett A, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:528–36.

45. Strydom A, Chan T, King M, Hassiotis A, Livingston G. Incidence of dementia in older adults with intellectual disabilities. Res Dev Disabil. 2013 Jun;34(6):1881–5.

46. Bush A, Beail N. Risk Factors for Dementia in People With Down Syndrome: Issues in Assessment and Diagnosis. Am J Ment Retard. 2004 Mar 1;109(2):83–97.

47. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. N Engl J Med. 2006 Oct 12;355(15):1525–38.

48. Banerjee S. The use of antipsychotic medication for people with dementia: Time for action. Lond Dep Health [Internet]. 2009 [cited 2014 Nov 22]; Available from: http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf

49. Dementia and People with Learning Disabilities - Guidance on assessment, diagnosis, treatment and support of people with learning disabilities who develop dementia. Royal College of Psychiatrists and The British Psychological Society; 2009.

50. Espie CA. Sleep and disorders of sleep in people with mental retardati... : Current Opinion in Psychiatry [Internet]. [cited 2014 Nov 14]. Available from: http://journals.lww.com/co-psychiatry/Fulltext/2000/09000/Sleep_and_disorders_of_sleep_in_people_with_mental.7.aspx

51. Sajith SG, Clarke D. Melatonin and sleep disorders associated with intellectual disability: a clinical review. J Intellect Disabil Res. 2007 Jan 1;51(1):2–13.

52. Edelsohn GA, Schuster JM, Castelnovo K, Terhorst L, Parthasarathy M. Psychotropic Prescribing for Persons With Intellectual Disabilities and Other Psychiatric Disorders. Psychiatr Serv [Internet]. 2014 [cited 2014 Nov 22]; Available from: http://journals.psychiatryonline.org/Article.aspx?ArticleID=1777608